StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.50−0.44 (-2.21%)

Close on Nov 18, 2026Market cap $5.51BP/E –Yield –

Caris Life Sciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Caris Life Sciences's revenue for the twelve months ending Sep 30, 2026 was $1.05B, up 61.5% year over year. For fiscal 2025 it was $812.03M, up 97.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$812.03M+97.0%
FY2024Dec 31, 2024$412.26M+34.7%
FY2023Dec 31, 2023$306.13M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$275.36M+27.0%
Q2 FY2026Jun 30, 2026$263.71M+45.4%
Q1 FY2026Mar 31, 2026$216.17M+78.8%
Q4 FY2025Dec 31, 2025$292.89M+125.4%
Q3 FY2025Sep 30, 2025$216.83M+113.4%
Q2 FY2025Jun 30, 2025$181.40M+81.3%
Q1 FY2025Mar 31, 2025$120.92M–
Q4 FY2024Dec 31, 2024$129.92M–
Q3 FY2024Sep 30, 2024$101.62M–
Q2 FY2024Jun 30, 2024$100.05M–

More Caris Life Sciences figures

See a number that looks wrong?